The peripheral nervous system can be vulnerable to the toxic action of several drugs since it
is not protected as effectively as the central nervous system from noxious exogenous agents …

Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease
progression in some patients, leading to progression-free survival (PFS) and overall survival …

PURPOSE: In patients with stage III colon cancer (CC) whose tumors demonstrate
microsatellite instability (MSI), the efficacy of adjuvant fluoropyrimidine (FP) with or without …

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment
of non-hematologic malignancies. Many patient-related variables (eg, age, tumor type …

Background The cardiovascular risk of angiogenesis inhibitors is not well-quantified. We
hypothesized that, compared to direct vascular endothelial growth factor (VEGF) inhibitors …

Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as
additional conduits for metastatic spread. The identification of growth factor receptor …

Purpose The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed
to investigate the safety and efficacy of adding bevacizumab to modified FOLFOX6 …

Colon cancer is one of the leading tumours in the world and it is considered among the big
killers, together with lung, prostate and breast cancer. In the recent years very important …

Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an
important part of standard therapy in multiple cancer indications. With expanded clinical …

Thrombocytopenia is a common problem in cancer patients. Aside from bleeding risk,
thrombocytopenia limits chemotherapy dose and frequency. In evaluating thrombocytopenic …